(±)9-HETE-d8
(Synonyms: (±)9-Hydroxyeicosatetraenoic Acid-d8) 目录号 : GC46268
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
(±)9-HETE-d8 is intended for use as an internal standard for the quantification of (±)9-HETE by GC- or LC-MS. (±)9-HETE is a monohydroxy fatty acid formed by lipid peroxidation of arachidonic acid , as well as by rat liver microsomal cytochrome P450 (CYP).1,2 Plasma levels of (±)9-HETE are elevated in patients with angiographically defined coronary artery disease.3
1.Powell, W.S., and Rokach, J.Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acidBiochim. Biophys. Acta1851(4)340-355(2014) 2.Capdevila, J., Yadagiri, P., Manna, S., et al.Absolute configuration of the hydroxyeicosatetraenoic acids (HETEs) formed during catalytic oxygenation of arachidonic acid by microsomal cytochrome P-450Biochem. Biophys. Res. Commun.141(3)1007-1011(1986) 3.Shishehbor, M.H., Zhang, R., Medina, H., et al.Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery diseaseFree Rad. Biol. Med.41(11)1678-1683(2006)
| Cas No. | N/A | SDF | |
| 别名 | (±)9-Hydroxyeicosatetraenoic Acid-d8 | ||
| Canonical SMILES | OC(C/C([2H])=C([2H])\C/C([2H])=C([2H])\CCCCC)([2H])/C([2H])=C/C([2H])=C([2H])\CCCC(O)=O | ||
| 分子式 | C20H24D8O3 | 分子量 | 328.5 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 50 mg/ml,PBS (pH 7.2): 0.5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0441 mL | 15.2207 mL | 30.4414 mL |
| 5 mM | 0.6088 mL | 3.0441 mL | 6.0883 mL |
| 10 mM | 0.3044 mL | 1.5221 mL | 3.0441 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。